Algorae Pharmaceuticals Issues New Shares and Confirms Compliance in Cleansing Notice

Living Cell Technologies ( (AU:1AI) ) has provided an announcement.

Algorae Pharmaceuticals has issued fully paid ordinary shares, as detailed in an Appendix 2A lodged with the ASX, and confirmed these securities were issued without a formal disclosure document under the fundraising provisions of the Corporations Act. The company stated it is up to date with its financial reporting and continuous disclosure obligations and that there is no excluded information that would need to be revealed to the market at this time.

This cleansing notice allows the newly issued shares to be freely traded on the market, signalling that Algorae considers its disclosure record sufficient for investors to assess the company’s position. For shareholders and potential investors, the confirmation of regulatory compliance and absence of undisclosed price-sensitive information reduces uncertainty around the new issuance and supports ongoing secondary market liquidity in the stock.

The most recent analyst rating on (AU:1AI) stock is a Hold with a A$0.02 price target. To see the full list of analyst forecasts on Living Cell Technologies stock, see the AU:1AI Stock Forecast page.

More about Living Cell Technologies

Algorae Pharmaceuticals Limited is an Australia-listed biotechnology company focused on pharmaceutical development. The company is traded on the ASX under the ticker 1AI and operates from Melbourne, reflecting its positioning within the local life sciences and drug development sector.

YTD Price Performance: 14.29%

Average Trading Volume: 1,506,343

Technical Sentiment Signal: Hold

Current Market Cap: A$28.18M

For a thorough assessment of 1AI stock, go to TipRanks’ Stock Analysis page.